Galaxy Surfactants (NSE: GALAXYSURF) Q3 FY26 results signal portfolio resilience as specialty growth offsets global surfactant pressures
Natural Capsules (NSE: NATCAPSUQ) Q3 FY26 results signal operational recovery after regulatory shock, but fermentation execution risk still looms
Read More 4 minute read Pharma Industry News Travere Therapeutics stock soars 25% as FDA skips advisory panel for FSGS drug FILSPARI Travere stock jumped 25% after the FDA waived an advisory panel for its FSGS drug. Find out why FILSPARI could transform the rare kidney disease market. byPallavi MadhirajuSeptember 10, 2025